Aquestive Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 4, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 4, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Chief Executive Officer Daniel Barber adopted a written sales plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act (the "Barber Plan") on June 14, 2024. The Barber Plan commenced on September 13, 2024 and ends on September 30, 2025. The maximum number of shares to be sold under the Barber Plan is 650,055 shares and no shares have been sold as of the date of this Report; the actual number of shares sold will be dependent on the satisfaction of certain conditions set forth in the Barber Plan.
Senior Vice President Peter Boyd adopted a written sales plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act (the "Boyd Plan") on September 11, 2024. The Boyd Plan commences on December 13, 2024 and ends on December 12, 2025. The maximum number of shares to be sold under the Boyd Plan is 35,000 shares; the actual number of shares sold will be dependent on the satisfaction of certain conditions set forth in the Boyd Plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.